A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.
Epistemonikos ID: e5abaa1d42e4e621ed939fdcaa900868f1f48024
First added on: Feb 19, 2024